Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
出版年份 2019 全文链接
标题
Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
作者
关键词
-
出版物
Cancers
Volume 11, Issue 9, Pages 1359
出版商
MDPI AG
发表日期
2019-09-13
DOI
10.3390/cancers11091359
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
- (2019) Kim M. Keppler-Noreuil et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Hereditary gastric cancer: what’s new? Update 2013–2018
- (2019) Rachel S. van der Post et al. Familial Cancer
- E-cadherin: Its dysregulation in carcinogenesis and clinical implications
- (2018) Sonia How Ming Wong et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials
- (2018) Xuan Li et al. PLoS One
- A proteomic landscape of diffuse-type gastric cancer
- (2018) Sai Ge et al. Nature Communications
- E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function
- (2018) Tanis D. Godwin et al. Gastric Cancer
- Maximising the potential of AKT inhibitors as anti-cancer treatments
- (2017) Jessica S. Brown et al. PHARMACOLOGY & THERAPEUTICS
- Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer
- (2017) Sharon Pattison et al. PLoS One
- Three-Dimensional Gastrointestinal Organoid Culture in Combination with Nerves or Fibroblasts: A Method to Characterize the Gastrointestinal Stem Cell Niche
- (2016) Agnieszka Pastuła et al. Stem Cells International
- Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
- (2015) Ramesh K. Ramanathan et al. CANCER
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- (2015) Joan Montero et al. CELL
- 338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
- (2015) A. Tolcher et al. EUROPEAN JOURNAL OF CANCER
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers
- (2015) Rachel S van der Post et al. JOURNAL OF MEDICAL GENETICS
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine
- (2015) Jeng-Wei Lu et al. MEDICAL ONCOLOGY
- Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells
- (2015) B. J. Telford et al. MOLECULAR CANCER THERAPEUTICS
- Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
- (2015) Marjorie J. Lindhurst et al. Scientific Reports
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- Hereditary Diffuse Gastric Cancer Syndrome
- (2015) Samantha Hansford et al. JAMA Oncology
- E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition
- (2014) Augustine Chen et al. BMC CANCER
- E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis
- (2014) Min Lu et al. MOLECULAR CELL
- voom: precision weights unlock linear model analysis tools for RNA-seq read counts
- (2014) Charity W Law et al. GENOME BIOLOGY
- BH3 profiling in whole cells by fluorimeter or FACS
- (2013) Jeremy Ryan et al. METHODS
- Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells
- (2013) PREEDAKORN CHUNHACHA et al. Oncology Letters
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain
- (2011) E. J. Meuillet CURRENT MEDICINAL CHEMISTRY
- MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
- (2011) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination
- (2011) H. Jo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
- (2010) E. J. Meuillet et al. MOLECULAR CANCER THERAPEUTICS
- Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
- (2010) Wen-I Wu et al. PLoS One
- Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes
- (2010) J. A. Ryan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Methodological approaches in application of synthetic lethality screening towards anticancer therapy
- (2009) D Canaani BRITISH JOURNAL OF CANCER
- Inhibitor hijacking of Akt activation
- (2009) Tatsuya Okuzumi et al. Nature Chemical Biology
- The cell-cell adhesion molecule E-cadherin
- (2008) F. van Roy et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Activated Akt as an indicator of prognosis in gastric cancer
- (2008) Caterina Cinti et al. VIRCHOWS ARCHIV
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started